For patients facing certain solid tumors, a positive scan can feel like a cruel reprieve. It confirms the disease is present, but often reveals a target for which no precise therapy exists. This gap, between diagnostic imaging and effective treatment, is the clinical and commercial space where Starget Pharma is placing its bet. The Israeli biotech is developing a class of drugs designed to be both the spotlight and the sniper, using proprietary peptides to deliver radioactive isotopes directly to cancer cells for imaging and destruction [Starget, Unknown].
With $38 million raised to date and a fresh $18 million Series A, the company is moving its lead candidate toward the clinic, aiming to prove its platform can address some of oncology's most stubborn challenges [Calcalist/CTech, 2026].
A Platform Built on Backbone Dynamics
Starget's technical wedge is its 'Backbone Dynamics' peptide platform. In radiopharmaceuticals, the targeting molecule,often a peptide or antibody,must be exquisitely specific to avoid damaging healthy tissue. Starget's approach uses backbone-cyclized peptide chemistry, a method that locks the molecule into a stable, three-dimensional shape. This rigidity, combined with in-silico AI design tools, is intended to create radioligands with optimized binding to tumor-specific receptors and favorable pharmacokinetics for clearance from the body [Starget, Unknown].
The platform is designed for a theranostic approach, meaning each program yields a matched pair: one compound for diagnostic imaging (like a PET scan tracer) and another, chemically similar compound for therapeutic radiation delivery. This allows clinicians to first confirm the tumor expresses the target and absorbs the tracer, then treat the same patient with the therapeutic version. The company's pipeline lists programs targeting receptors like CCK2R and GRPR, which are implicated in cancers such as medullary thyroid carcinoma and prostate cancer [Starget, Unknown].
The Clinical Roadmap and U.S. Footprint
The Series A proceeds are earmarked for advancing Starget's pipeline into clinical development [Opportunity Louisiana, Feb 2026]. The lead program is a first-in-class theranostic pair targeting the SSTR3 receptor for potential use in sarcoma, neuroendocrine tumors (NETs), and malignant melanoma. A Phase 1b trial for a different, undisclosed peptide radioligand was previously supported by a $5.1 million investment from the Cancer Focus Fund [Starget Pharma, 2024].
A critical, less flashy component of Starget's strategy is its manufacturing and translational partnership. The company has a strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Shreveport, Louisiana [Morningstar, Feb 2026]. This ties Starget's Israeli discovery engine to U.S.-based clinical production capabilities, a necessary step for trials and eventual commercialization. Stephen Lokitz, executive director of CMIT, has toured the facility with the Starget team, signaling operational alignment [Expansion Solutions, Feb 2026].
Pre-Series A (cumulative) | 20 | M USD
Series A (Feb 2026) | 18 | M USD
Total Disclosed Funding | 38 | M USD
The Team and Investor Conviction
The founding team blends entrepreneurial and scientific expertise. CEO Sigal Kalmanson Cusnir leads the company, with co-founder Ronen Clemson bringing a track record that includes co-founding and serving on the board of Urogen Pharma Ltd., a commercial-stage urology company [Equilar ExecAtlas, Unknown]. Ronen Kalmanson is listed as chairman and co-founder [Crunchbase, Unknown]. Dr. Michel Afargan, with the title Head of Drug Development & Radiopharmaceutical Strategies, adds depth to the scientific leadership [LinkedIn, retrieved 2026].
Their progress has attracted specialized oncology investors. The recent $18 million Series A was led by Ilex Medical, with participation from existing backers the Louisiana Growth Fund and the Cancer Focus Fund [PR Newswire, Feb 2026]. The Cancer Focus Fund's earlier investment specifically supported clinical trial work, indicating an investor base willing to fund the expensive, regulated path from bench to bedside.
| Role | Name | Key Background |
|---|---|---|
| CEO & Co-Founder | Sigal Kalmanson Cusnir | Leads the clinical-stage radiopharmaceutical company [Biomed Israel, May 2025]. |
| Co-Founder | Ronen Clemson | Serial entrepreneur and former Co-Founder/Board Member of Urogen Pharma Ltd. [Equilar ExecAtlas, Unknown]. |
| Chairman & Co-Founder | Ronen Kalmanson | Listed as company chairman [Crunchbase, Unknown]. |
| Head of Drug Development | Dr. Michel Afargan | Leads radiopharmaceutical strategy and development [LinkedIn, retrieved 2026]. |
Navigating a High-Stakes Landscape
The ambition is clear, but the path is lined with the inherent risks of drug development. Starget's platform, while proprietary, enters a radiopharmaceutical field that has grown increasingly crowded and competitive since the landmark approvals of drugs like Lutathera and Pluvicto. The company's differentiation rests on the specificity of its backbone-cyclized peptides and its AI-driven design cycle, claims that will ultimately be validated or refuted by clinical data on safety and efficacy.
Furthermore, the focus on 'hard-to-treat' solid tumors is a strategic choice that carries its own calculus. These are areas of high unmet need, which can mean more receptive regulators and less commercial competition. They can also mean a more challenging biological environment for any drug to prove effective. The company's ability to select the right tumor targets and patient populations for its initial trials will be crucial.
Key near-term milestones are clinical. The capital is in place to advance multiple programs toward clinical entries planned for 2026 [Investing.com, Feb 2026]. Success will be measured in trial initiations, then in early clinical readouts on imaging quality, safety, and tumor response. The CMIT collaboration must also prove its worth, smoothly translating discovered compounds into clinical-grade material for these studies.
For patients with advanced sarcoma or progressive neuroendocrine tumors, the current standard of care often involves sequential lines of chemotherapy or targeted therapy, with diminishing returns and significant side effects. Radiopharmaceuticals like those Starget is developing represent a different paradigm: a systemic treatment that aims to be highly localized, using radiation delivered with cellular precision. The next twelve months will test whether Starget's smart ligands can make the difficult transition from a compelling platform to a clinical candidate that changes that standard.
Sources
- [Starget, Unknown] Company Website | https://stargetpharma.com/
- [Calcalist/CTech, 2026] Funding Report | https://www.calcalistech.com/
- [Biomed Israel, May 2025] Company Abstract | https://biomedisrael.org.il/
- [Opportunity Louisiana, Feb 2026] Series A Announcement | https://www.opportunitylouisiana.com/
- [Starget Pharma, 2024] Cancer Focus Fund Investment | https://stargetpharma.com/starget-pharma-and-cancer-focus-fund-announce-5-1-million-investment-to-support-phase-1b-clinical-trial-of-novel-peptide-radioligand-for-precision-cancer-therapy/
- [Morningstar, Feb 2026] CMIT Collaboration | https://www.morningstar.com/
- [Expansion Solutions, Feb 2026] CMIT Facility Tour | https://www.expansionsolutionsmagazine.com/
- [PR Newswire, Feb 2026] Series A Lead Investor | https://www.prnewswire.com/
- [Equilar ExecAtlas, Unknown] Ronen Clemson Profile | https://people.equilar.com/bio/org/starget-pharma/10617504
- [Crunchbase, Unknown] Ronen Kalmanson Profile | https://www.crunchbase.com/
- [LinkedIn, retrieved 2026] Dr. Michel Afargan Profile | https://www.linkedin.com/in/dr-michel-afargan-66958175/
- [Investing.com, Feb 2026] Clinical Entry Plans | https://www.investing.com/